The pharmacology of donepezil: a new treatment for Alzheimer’s disease

Bibliography

• HOFFMAN A, ROCCA WA, BRAYNE C: The prevalence ofdementia in Europe: a collaborative study of 1980-1990 findings. Int. J. Epidemiol. (1991) 20:736–748.
   PubMedGoogle Scholar
• GRAY AM, FENN P: Alzheimer's disease: the burden ofillness in England. Health Trends (1993) 25:31–37.
   PubMedGoogle Scholar
• SMALL GW, RABINS PV, BARRY PB et al.: Diagnosis andtreatment of Alzheimer's disease and related disorders. JAMA (1997) 278:1363–1371.
   PubMed Web of Science ®Google Scholar
• SUMMERS WK, MAJOVSKI, MARSH GM etal.: Oral tetrahy-droaminoacridine in long term treatment of senile dementia, Alzheimer type. New Engl. J. Med. (1986) 315:1241–1245.
   Google Scholar
• •This study is of interest, although flawed, as it was the catalyst for the current development of AChEI for treatment of AD.
   Google Scholar
• KNAPP MJ, KNOPMAN DS, SOLOMAN PR et al.: A 30-week randomised controlled trial of high dose tacrine in patients with Alzheimer's disease. JAMA (1994) 271:985–991.
   PubMed Web of Science ®Google Scholar
• •First pivotal US Phase III study proving efficacy in AD.
   Google Scholar
• NOCHI S, ASAKAWA N, SATO T: Kinetic study on the inhibition of acetyl- cholinesterase by 1-benzy1-4- [(5,6 dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride (E2020). Biol. Pharm. Bull. (1995) 180:1145–1147.
   Google Scholar
• GALLI A, MORI F, BENINI L et al.: Acetylcholinesterase protection and the anti-diisopropylflurophosphate efficacy of E2020. Eur. J. Pharmacol. Environ. Toxicol Pharmacol. (1994) 270:189–193.
   PubMed Web of Science ®Google Scholar
• NAKAMURA S, YUKAWA M, MIMORI Y: Abnormalproperties of acetylcholinesterase inhibitors localised in senile plaque (abs.no.419). Neurobiol. Aging (1994) 15 (Suppl. 1):S102.
   Google Scholar
• ROGERS S, YAMANISHI Y, YAMATSU K: E2020-thepharmacology of a piperidine cholinesterase inhibitor. In: Cholinergic Basis for Alzheimer's Therapy Becker R, Giacobini E (Eds.), Birkhauser, Boston, USA (1990314–320.
   Google Scholar
• FLICKER DM, DEAN RL, WATKINS DL: Behavioral andneurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat et al.: Pharmacol. Biochem. Behav. (1983) 18:973–981.
   PubMed Web of Science ®Google Scholar
• KAWASHIMA K, SATO A, YOSHIZAWA M et al.: Effects ofthe centrally acting cholinesterase inhibitors tetrahy-droaminoacridine and E2020 on the basal concentra-tion of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn-Schmied. Arch. Pharmacol. (1994) 350:523–528.
   PubMed Web of Science ®Google Scholar
• DAWSON GR, IVERSEN SD: The effects of novel cholin-esterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav. Brain Res. (1993) 30(57):143–153.
   Google Scholar
• VAN DER STAAY FJ, HINTZ VC, SCHMIDT BH: Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholines-terase inhibitors on Morris water escape behaviour in young adult rats. J. Pharmacol. Exp. Ther. (1996) 278:697–708.
   PubMedGoogle Scholar
• ROGERS SL, FRIEDHOFF LT: Pharmacokinetic and pharmacodynamic profile of donepezil HC1 following single oral doses. Br. J. Clin. Pharmacol (1998) 46 (Suppl. 0:1–6.
   Google Scholar
• ROGERS SL, WALTERS EJ, FRIEDHOFF LT: The pharma-cokinetics (PK) and pharmacodynamics (PD) of E2020 (R S)-I-benzy1-4- (5, 6 dimethoxy-1-indanon) -2-y1) methylpiperidine hydrochloride), a novel inhibitor of acetylcholinesterase (AChE): implications for use in the treatment of Alzheimer's disease (abstract). Neurobiol. Aging (1992) 13(0:496.
   Google Scholar
• MIHARA M, OHNISHI A, TOMONO Y et al.: Pharmacoki-netics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol (1993) 31:223-229. Exp. Opin. Pharmacother. (1999) 1(1)
   Google Scholar
• OHNISHI A, MIHARA M, KAMAKURA H et al.: Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy, young and elderly subjects. J. Clin. Pharmacol (1993) 33 :1086–1091.
   PubMed Web of Science ®Google Scholar
• TISEO PJ, PERDOMO CA, FRIEDHOFF LT: Metabolism and elimination of 14C-donepezil in healthy volunteers, a single dose study. Br. J. Clin. Pharmacol. (1998) 46\(Suppl. 0:19–24.
   Google Scholar
• ROGERS S L, COOPER NM, SUKOVATY R et al: Pharma-cokinetic and pharmacodynamic profile of donepezil HC1 following multiple doses. J. Clin. Pharmacol. (1998) 46(Suppl.)
   Google Scholar
• TISEO PJ, VARGAS R, PERDOMO CA, FRIEDHOFF LT: An evaluation of the pharmacokinetics of donepezil HC1 in patients with impaired hepatic function. Br. J. Clin. Pharmacol. (1998) 46\(Suppl. 0:51–55.
   Google Scholar
• EISAI AMERICA, INC.: US Package Insert: Aricept (donepezil hydrochloride tablets). (September 1998).
   Google Scholar
• THAL LJ, SWARTZ G, SANO M et al.: A multicentre double-blind study of controlled-release physostig-mine for the treatment of symptoms secondary to Alzheimer's disease. Neurology (1996) 47:1389–1395.
   PubMed Web of Science ®Google Scholar
• CHATELIER G, A, LACOMBLEZ L: Tacrine and Lecithin in senile dementia of the Alzheimer type; a multi-centre trial. Groupe Francais et Etude de la Tetrahydroami-noacridine. Br. Med. J. (1990) 300:495–499.
   Google Scholar
• MOLLOY GW, GUYATT GH, WILSON DB et al.: Effect of Tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. Can. Med. Assoc. J. (1991) 144:29–34.
   PubMed Web of Science ®Google Scholar
• LEBER P: Guidelines for the clinical evaluation of anti-dementia drugs. US FDA, Washington DC, USA (1990).
   Google Scholar
• ROSEN WG, MOHS RC, DAVIS KL: A new rating scale for Alzheimer's disease. Am. J. Psychiat. (1 9 8 4) 141:1356-1364.
   Google Scholar
• •The description of the ADAS which has become the standard test of cognition in drug trials in dementia.
   Google Scholar
• ROGERS SL, FRIEDHOFF LT, THE DONEPEZIL STUDY GROUP: The efficacy and Safety of Donepezil in patients with Alzheimer's disease: results of the US multicentre, randomised, double-blind, placebo-controlled trial. Dementia (1996) 7:293–303.
   PubMedGoogle Scholar
• SCHNEIDER LS, OLIN JT, DOODY RS et al.: The Alzheimer's disease Cooperative Study: validity and reliability of the Alzheimer's disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis. Assoc. Disord. (1997) 11 (Suppl. 2):S22–S32.
   Google Scholar
• ROGERS SL, DOODY RS, MOHS RC et al.: Donepezil improves cognition and global function in Alzheimer's disease. A 15 week, double-blind, placebo-controlled study. Arch. Int. Med. (1998) 158:1021–1031.
   Google Scholar
• ••The first pivotal study to show efficacy of donepezil in theUS with benefits maintained during a 3 week washout.
   Google Scholar
• ROGERS SL, FARLOW MD, DOODY RS et al. A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology (1998) 50:136–145.
   PubMed Web of Science ®Google Scholar
• ••A classic study the major pivotal Phase III trial in US.
   Google Scholar
• BURNS A, ROSSOR M, HECKER J et al.: The Effects of Donepezil in Alzheimer's disease-Results from a Multinational Trial. Dement. Geriatr. Cogn. Disord. (1999) 10:237–244.
   PubMed Web of Science ®Google Scholar
• ••The non-US version of [30] using same protocol andproducing similar results but demonstrating greater efficacy for 10 mg rather than 5 mg.
   Google Scholar
• BERG L, MILLER JP, BATY J et al: Mild senile dementia of the Alzheimer type: 4 evaluations of intervention. Ann. Neurol. (1992) 31:242–209.
   PubMedGoogle Scholar
• TEUNISSE S, DERIX M, VAN CREVEL H: Assessing the severity of dementia, patient and caregiver. Arch. Neurol. (1991) 48:274–277.
   PubMed Web of Science ®Google Scholar
• •Paper describing the IDDD scale for measuring functional change.
   Google Scholar
• FRIEDHOFF LT, ROGERS SL: Donepezil lengthens time to loss of activities of daily living in patients with mild to moderate Alzheimer's disease-results of prelimi-nary evaluation. Neurology (1997) 48 (5):A100 (P02.026).
   Google Scholar
• BLAU TH: Quality of life, social indicators and criteria of change. Prof Psycho]. (1977) 8:464–473.
   Google Scholar
• ROGERS S. FRIEDHOFF L: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of the US multicentre open label extension study. Eur. Neuropsychophar-macol. (1998) 8:67–75.
   PubMedGoogle Scholar
• •An open label continuation study of [29] showing mainte-nance of effects for a further 26 weeks.
   Google Scholar
• STERN RG, MOHS RC, DAVIDSON M et al.: A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am. J. Psychiat. (1994) 151(3)390–396.
   Google Scholar
• PRATT RD, GELDMACHER DS., PERDOMO CA: An evalua-tion of the long-term efficacy of donepezil in patients from a Phase III clinical extension trial [poster/presentation]. Annual Meeting of the American Academy of Neurology. Toronto, USA (1999).
   Google Scholar
• DOODY RS, GELDMACHER DS, PRATT RD et al.: Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration. J. Neurol. (1999) 246\(Suppl. 1):P226 (I 52).
   Google Scholar
• MCRAE T, ORAZEM J: Donepezil safety and efficacy in a large, community-based, open-label trial. J. Neurol. (1999) 246\(Suppl. 1):P224 (152).
   Google Scholar
• KAUFER D, CATT K, POLLOCK B et al.: Donepezil in Alzheimer's disease: relative cognitive and neuropsy-chiatric response and impact in caregiver distress [poster]. American Geriatrics Society. Seattle, USA (1998). Poster 198.
   Google Scholar
• MATTHEWS H, KORBEY J, WILKINSON DG et al.: Firstyear results of donepezil use in a UK clinic for AD [Poster]. XI Congress of World Psychiatric Association. Hamburg, Germany (1999).
   Google Scholar
• RASKIND MA, CYRUS PA, RUZICKA BB, GULANSKI BI: The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. J. Clin. Psychiat. (1999) 60(5):318–25.
   PubMedGoogle Scholar
• KAUFER D: Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibi-tors on neuropsychiatric symptoms in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. (1998) 9\(Suppl. 2):8–14.
   Google Scholar